Drug intelligence / Profile preview

izenivetmab

Development stage: Unknown
Lead developer: Zoetis
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

Izenivetmab is a monoclonal antibody designed for veterinary use to alleviate pain associated with osteoarthritis in dogs. It is administered as a single injection that provides pain relief for up to three months. Izenivetmab works by targeting and neutralizing **nerve growth factor (NGF)**, a key mediator of pain and inflammation, resulting in improved mobility and reduced pain in treated dogs[4][8][10][12]. Developed and backed by more than a decade of research, izenivetmab demonstrated a favorable safety profile and efficacy in a nine-month field study[4].

Brand names: Lenivia

Targets

NGF (Nerve growth factor)

Beyond the preview

Go deeper on izenivetmab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on izenivetmab.

Explore the full profile